Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Hims & Hers Health (NYSE:HIMS) said it is holding discussions with Novo Nordisk (NYSE:NVO) to make the Danish drugmaker's ...

Hims & Hers Health (HIMS) traded ~6% higher on Tuesday after the telehealth platform, with its Q3 2025 results, said it is in ...

Shares of Hims & Hers Health ($HIMS) rallied on Tuesday after management said it’s in discussions with Novo Nordisk ($NVO) to ...

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added ...

Less than six months after ending a short-lived partnership, US telehealth firm Hims & Hers (Nasdaq: HIMS) and Danish ...

Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...

Now, it’s worth noting Stock Advisor’s total average return is 1,036% — a market-crushing outperformance compared to 191 % ...

Hims & Hers Health has appointed Deb Autor as ​its first chief policy officer to lead ‌public policy and government functions ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

Investing.com -- Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 1.5% on Monday after the health and wellness platform announced a new $250 million share repurchase program. The authorization comes ...

After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.